OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has engaged the services of CFN Media as part of an effort that seeks to attract high-quality investors. The company also plans to use the partnership to broaden its product’s target market.
CFN Media Agreement
CFN Media will conduct a 2-month investor and market visibility program as part of the agreement. The company’s President, Frank Lane, has welcomed the partnership, which he says will help millions of people gain access to their high-quality cannabinoid psoriasis cream. The Israel-based company plans to use its presence in the cannabinoid sector to promote OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) offerings.
“We are very excited to cooperate, again, with CFN Media. In the near future, OWC will report developments that we believe are material. CFN has proven themselves as a reliable and professional media outlet with exceptional editorial skills. Together with their video interviews we will have the best channel to convey our message to the investment community,” said OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) CEO, Mordechai Bignitz.
CFN Media’s collaboration builds on a similar agreement signed with Mediq Innovation partners last month. Under the items of that agreement, the German-based company has agreed to market OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) products in Europe.
Mediq’s will offer both strategic and scientific assistance geared towards developing a commercial market for OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) proprietary cannabinoid products. Plans are already underway to unveil products in Germany since the country’s law and regulations allow for the sale of non-smokable cannabis.
Germany’s health care sector will be key for growth as it offers reimbursement for medical cannabis. Other countries where cannabis has a legal status do not yet offer reimbursement for cannabinoid treatment(s). Scientific collaboration should also benefit the company as it continues to explore new products in a bid of taking advantage of growing demand for cannabis products.
“We’re looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany. Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP’s proprietary cannabinoid-based topical psoriasis cream is the right product at the right time,” said Mediq Managing Director, Jan Wende.
Separately, OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has confirmed that its wholly owned Israeli subsidiary, One World Cannabis Ltd, has designed the road map for a Multiple Myeloma study. The study builds on promising results from an earlier vitro study. The purpose of the next phase of study is to investigate the dose levels and delivery systems for a future planned study on human patients.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $OWCP and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.